AICDA and acute lymphoblastic leukemia: The main indication was lymphoma (n = 1851; 99% autologous), followed by ALL (n = 379; 89% autologous), other malignancies i.e., myeloma, AID (n = 294; 95% autologous) (Fig. 6).